BrightSpring Health Services, Inc. — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
BrightSpring reported Q3 2026 net revenue of $4,213M (+26.4% YoY) and Adjusted EBITDA of $228M (+42.0% YoY). The company raised full-year 2026 revenue guidance to $15,900–$16,125M (+23.2–24.9%) and Adjusted EBITDA guidance to $850–$860M (+37.6–39.3%). Leverage improved to 1.79x from 2.15x in Q2 2026. Growth was driven by Pharmacy Solutions (+26% revenue, +43% EBITDA) and Provider Services (+31% revenue, +30% EBITDA). The Amedisys and LHC branches acquisition is expected to contribute ~$35M Adjusted EBITDA in 2026.
Why this rating
Strong operational execution and upward guidance revision on 2.3B company is meaningful but not transformational. Represents solid operating leverage and execution, not material change in business scale or trajectory.
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.